Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Why PODD Stock surged +2.63% Today — RQD Quant Desk Flash
Insulet Corporation (PODD) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (71.6% gross margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $153.61 (+2.63% 1D, market cap $10.38B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, PODD ranks #58 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PODD compare to GMED and BAX in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (72/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a C+ grade (69/100 RQD, P/E 20.7x, ROIC 8.7%, cap $10.48B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PODD?
▼
Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (71.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($377.7M FCF) & 71.6% Gross Margin
Altman Z-Score 5.72 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
Macro rate sensitivity & RSI-14 (59.3) create a -11 pt regime headwind
⚔️ Adversarial Opposing Case: Why the PODD Bull Thesis Could Fail
Even with a 72/100 (B) score, PODD faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($141.27) or 200D SMA ($176.78) invalidates the momentum regime and cuts Target Base ($163.29) toward Bear Floor ($125.96).
Why PODD Stock surged +2.63% Today — RQD Quant Desk Flash
Insulet Corporation (PODD) surged +2.63% to $153.61, trading at 12% of its 52-week range ($126.4 – $354.88). High-quality cash engine (71.6% gross margin, 20% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 12% of its 52-week range ($126.4 – $354.88) with RSI-14 at 59.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.1% around $153.61 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 71.6% gross margin and $377.7M annual free cash flow.
Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
openPR.com report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
S&P 500 postmarket decliners after Tuesday's close included CoStar Group, NXP Semiconductors, Robinhood, Teradyne and Seagate.
Omnipod Discover launch puts Insulet’s data platform in focus Insulet (PODD) has rolled out Omnipod Discover nationwide in the US, extending a web-based data platform that earlier limited-release users and healthcare pro
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PODD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
PODD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +30.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PODD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PODD. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PODD)
1. Head-to-Head Health Care Peer Comparison (PODD vs. GMED, BAX, PEN, SOLV)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Insulet Corporation (PODD) ranks #58 by composite RQD confidence (72/100, grade B) and #104 by equity capitalization ($10.38B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PODD
ACTIVE
Insulet Corporation | B | 72/100 | 42.8x | 71.6% | 20.4% | +2.63% | $10.38B | Benchmark Subject |
| GMED Globus Medical Inc. | C+ | 69/100 | 20.7x | 67.4% | 8.7% | +1.81% | $10.48B | /gmed-vs-podd → |
| BAX Baxter International Inc. | D | 50/100 | — | 30.1% | -2.4% | +5.30% | $11.90B | /bax-vs-podd → |
| PEN Penumbra Inc. | D+ | 57/100 | 71.4x | 67.1% | 10.6% | +0.75% | $12.57B | /pen-vs-podd → |
| SOLV Solventum Corporation | D | 44/100 | 9.1x | 53.5% | 18.7% | +4.21% | $13.84B | /solv-vs-podd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001145197 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insulet Corporation (PODD) reported GAAP revenue of $2.71B (+30.7% vs. FY2024 revenue of $2.07B , and +59.6% cumulative change since FY2023) , GAAP net income of $247.1M, operating cash flow of $569.3M, and free cash flow of $377.7M (+23.7% YoY). On the balance sheet, PODD closed FY2025 with $3.19B in total assets against $753.8M in total debt (Altman Z-Score: 5.72, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.71B | $247.1M | $569.3M | $377.7M | $3.19B | $753.8M |
| FY2024 (FY) | 2024-12-31 | $2.07B | $418.3M | $430.2M | $305.3M | $3.09B | $844.2M |
| FY2023 (FY) | 2023-12-31 | $1.70B | $206.3M | $145.7M | $69.3M | $5.82B | $1.36B |
3. PODD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $153.61 (+2.63% 1D, market cap $10.38B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, PODD ranks #58 in composite RQD confidence.
How does PODD compare to GMED and BAX in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (72/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a C+ grade (69/100 RQD, P/E 20.7x, ROIC 8.7%, cap $10.48B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PODD?
Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (71.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PODD trading relative to its 50-day, 200-day, and 52-week technical levels?
PODD last traded at $153.61 (+2.63% on volume of 1,772,797 shares), positioning the stock +8.74% above its 50-day simple moving average ($141.27) and -13.11% below its 200-day simple moving average ($176.78). Across its 52-week range of $126.40 to $354.88, PODD sits at the 11.9% percentile with a 14-day RSI of 59.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.1% ($144.24 to $162.98).
PODD — Insulet Corporation: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Insulet Corporation (PODD) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $153.61 (+2.63% 1D, market capitalization $10.38B).
- Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 20.4%, gross margin of 71.6%, operating margin of 17.5%, and free cash flow yield of 3.57%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (18/20): Incorporates a 0.99x equity beta, Altman Z-Score of 5.72, Piotroski F-Score of 8/9, and Debt/Equity of 0.46x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Insulet Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. — for specific products, customers, or revenue-generation detail. The source data reports gross margin of 71.6%, operating margin of 17.5%, and net margin of 9.1% per the market data section.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Insulet Corporation (PODD) reported $2.71B in annual revenue (up from $2.07B in FY2024, +30.7% YoY) and $247.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.70B revenue, $206.3M net income) through FY2025, PODD scaled operating cash flow to $569.3M and free cash flow to $377.7M, backed by $3.19B in total assets against $753.8M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (B • RQD 72/100): Strong cash generator (71.6% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $126.40 – $354.88 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 42.8x trailing P/E and 17.1x EV/EBITDA against 17.5% operating margins and a 0.99x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical/Dental Instruments (Health Care), PODD carries a macro regime beta of 0.99 and gross margin of 71.6%.
- Key Question #1: Can PODD sustain or expand its 17.5% operating margin and 20.4% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.71B and free cash flow of $377.7M, how will capital allocation balance growth reinvestment against $753.8M in total debt?
- Key Question #3: How sensitive is PODD's 36.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?
PODD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Insulet Corporation (PODD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
openPR.com report covering Insulet Corporation (PODD) market action, institutional positioning, and fundamental catalysts.
PODD Bull vs. Bear Conversation Board — What's Your Call at $153.61?
Per the RQD cash-engine pillar, ROIC of 20.4% and a strong forensic balance sheet (Altman Z 5.72; Piotroski F 8/9) support the rating.
Long PODD at $149.68 targeting $188.60. Per the RQD cash-engine pillar, ROIC of 20.4% and a strong forensic balance sheet (Altman Z 5.72; Piotroski F 8/9) support the rating.. Institutional whale score is 10/20 and the risk/reward vs. the $126.40 52-week low is skewed heavily in favor of bulls.
@BearTrap_Alert Shorting a 10/20 institutional whale-flow stock at $149.68 is dangerous when funds are rotating into Health Care.
Per the market data, trailing P/E of 42.8 and a 52-week range of $126.4 to $354.88 point to high valuation sensitivity, with macro regi
Sitting on the sidelines or leaning short PODD above $149.68. Per the market data, trailing P/E of 42.8 and a 52-week range of $126.4 to $354.88 point to high valuation sensitivity, with macro regime fit at 9/20.. Until Fundamental Cash Engine (19/20) and FCF yield (3.57%) inflect higher, upside is capped near $354.88.